MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011)

NCT00420420 ↗

Phase 2 Completed 144 enrolled Merck Sharp & Dohme LLC

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to test the efficacy and safety of an investigational medication for improving symptoms of Alzheimer's Disease. Subjects will receive either active medication or placebo for 28 days. Tests of memory, concentration will be included. Safety will be monitored using routine clinical and laboratory tests.

Timeline

Start: 2006-11
Primary completion: 2008-08
Completion: 2008-08

Outcome

Missed primary endpoint

registry MK0249 (5 mg) vs Placebo; p = 0.283; Mixed Models Analysis NCT00420420 ↗

registry MK0249 (5 mg) vs Placebo; p = 0.716; Mixed Models Analysis NCT00420420 ↗

paper There were no significant differences between treatments on primary and secondary endpoints at week 4 PMID 22272611 ↗

Publications

Results Egan M, Yaari R, Liu L, Ryan M, Peng Y, Lines C, Michelson D. Pilot randomized controlled study of a histamine receptor inverse agonist in the symptomatic treatment of AD. Curr Alzheimer Res. 2012 May;9(4):481-90. doi: 10.2174/156720512800492530.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MK-0249	Small molecule	5 mg	Oral